China Pharmaceutical Technology Company MICOT Raised ￥115 million in series pre-A round funding led by Norther Light Venture Capital, and followed by Tasly Holding Group, DT Capital Partners, and JunYing Growth Fund. The investment will be mainly used in clinical research of multiple drugs.
MICOT specializes in the research and development of new drugs for fatal major diseases such as cardiovascular and metabolic diseases, covering five major diseases such as ischemic heart disease, stroke, antithrombotic, nervous system injury, degenerative change and diabetes.
South Africa Today
Read more at VolaNews
